Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.

H.J. Broxterman, J. Lankelma, K. Hoekman

Research output: Contribution to JournalArticleAcademicpeer-review


Intrinsic resistance to anticancer drugs, or resistance developed during chemotherapy, remains a major obstacle to successful treatment. This is the case both for resistance to cytotoxic agents, directed at malignant cells, and for resistance to anti-angiogenic agents, directed at non-malignant endothelial cells. In this review, we will discuss mechanisms of resistance which have a bearing on both these conceptually different classes of drugs. The complexity of drug resistance, involving drug transporters, such as P-glycoprotein, as well as resistance related to the tissue structure of solid tumors and its consequences for drug delivery is discussed. Possible mechanisms of resistance to endothelial cell-targeted drugs, including inhibitors of the VEGF receptor and EGF receptor family, are reviewed. The resistance of cancer cells as well as endothelial cells related to anti-apoptotic signaling events initiated by cell integrin-matrix interactions is discussed. Current strategies to overcome resistance mechanisms are summarized; they include high-dose chemotherapy, tumor targeting of cytotoxics to improve tumor uptake, low-dose protracted (metronomic) chemotherapy and combinations of classical agents with anti-angiogenic agents. This review discusses primarily literature published in 2001 and 2002.
Original languageEnglish
Pages (from-to)111-27
JournalDrug Resistance Updates
Issue number3
Early online date1 Jun 2003
Publication statusPublished - 2003
Externally publishedYes


Dive into the research topics of 'Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.'. Together they form a unique fingerprint.

Cite this